Pentraxin-3 as a marker of advanced atherosclerosis results from the Bruneck, Army and Arfy studies

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Knoflach, Michael ^a   Kiechl, Stefan ^a   Mantovani, Alberto ^b,c   Cuccovillo, Ivan ^b   Bottazzi, Barbara ^b   Xu, Qingbo ^d   Xiao, Qingzhong ^d   Gasperi, Arno ^e   Mayr, Agnes ^e   Kehrer, Marlene ^e   Willeit, Johann ^a   Wick, Georg ^f  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e BRUNECK HOSPITAL   (Italy)

^f Laboratory of Autoimmunity   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PENTAXIN; PENTAXIN 3; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PENTRAXIN 3; SERUM AMYLOID P;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROSIS RISK FACTORS IN FEMALE YOUNGSTERS; ATHEROSCLEROSIS RISK FACTORS IN MALE YOUNGSTERS; BRUNECK STUDY; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; FEMORAL ATHEROSCLEROSIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; AGE; BLOOD; BLOOD VESSEL; INNATE IMMUNITY; MIDDLE AGED; PATHOLOGY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD VESSELS; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT; YOUNG ADULT;

EID: 84856527735     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031474     Document Type: Article

References (30)

1. Ross R, (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340: 115-126.
2. Hansson GK, Libby P, Schonbeck U, Yan ZQ, (2002) Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 91: 281-291.
3. Wick G, Knoflach M, Xu Q, (2004) Autoimmune and Inflammatory Mechanisms in Atherosclerosis. Annu Rev Immunol 22: 362-403.
4. Bottazzi B, Doni A, Garlanda C, Mantovani A, (2010) An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 28: 157-183.
5. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, et al. (2000) PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102: 636-641.
6. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, et al. (2006) The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol 45: 326-330.
7. Kaess BM, Vasan RS, (2011) Heart failure: Pentraxin 3-a marker of diastolic dysfunction and HF? Nat Rev Cardiol 8: 246-248.
8. Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, et al. (2007) Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 27: 161-167.
9. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, et al. (2004) Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354.
10. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, et al. (2008) Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 155: 75-81.
11. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM, (2009) Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 29: 594-599.
12. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, et al. (2002) Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22: e10-e14.
13. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, et al. (2009) Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Circulation 120: 699-708.
14. Kiechl S, Willeit J, (1999) The natural course of atherosclerosis. Arterioscler Thromb Vasc Biol 19: 1484-1498.
15. Kiechl S, Egger G, Mayr M, Wiedermann CJ, Bonora E, et al. (2001) Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 103: 1064-1070.
16. Knoflach M, Kiechl S, Kind M, Said M, Sief R, et al. (2003) Cardiovascular risk factors and atherosclerosis in young males: ARMY study (Atherosclerosis Risk-Factors in Male Youngsters). Circulation 108: 1064-1069.
17. Knoflach M, Kiechl S, Penz D, Zangerle A, Schmidauer C, et al. (2009) Cardiovascular risk factors and atherosclerosis in young women: atherosclerosis risk factors in female youngsters (ARFY study). Stroke 40: 1063-1069.
18. Baecke JA, Burema J, Frijters JE, (1982) A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 36: 936-942.
19. DeLong ER, DeLong DM, Clarke-Pearson DL, (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44: 837-845.
20. Rohde LE, Hennekens CH, Ridker PM, (1999) Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 84: 1018-1022.
21. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V, (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148: 209-214.
22. Back M, Ketelhuth DF, Agewall S, (2010) Matrix metalloproteinases in atherothrombosis. Prog Cardiovasc Dis 52: 410-428.
23. Olson FJ, Schmidt C, Gummesson A, Sigurdardottir V, Hulthe J, et al. (2008) Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis. J Intern Med 263: 626-635.
24. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, et al. (2008) Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol 215: 48-55.
25. Matsui S, Ishii J, Kitagawa F, Kuno A, Hattori K, et al. (2010) Pentraxin 3 in unstable angina and non-ST-segment elevation myocardial infarction. Atherosclerosis 210: 220-225.
26. Nishi K, Imamura T, Kitamura K, Ogawa T, Fujimoto S, et al. (2011) Associations of plasma pentraxin 3 and monocyte chemoattractant protein-1 concentrations with cardiovascular disease in patients with chronic kidney disease. Ren Fail 33: 398-404.
27. Xu Y, Ding X, Zou J, Liu Z, Jiang S, et al. (2011) Plasma Pentraxin 3 is Associated with Cardiovascular Disease in Hemodialysis Patients. Ren Fail 33: 998-1004.
28. Kanbay M, Ikizek M, Solak Y, Selcoki Y, Uysal S, et al. (2011) Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 33: 325-331.
29. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, et al. (2011) Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 6: 785-792.
30. Jylhava J, Haarala A, Kahonen M, Lehtimaki T, Jula A, et al. (2011) Pentraxin 3 (PTX3) is associated with cardiovascular risk factors: the Health 2000 Survey. Clin Exp Immunol 164: 211-217.